Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - Bolt Biotherapeutics reported a quarterly loss of $4.46 per share, which was better than the Zacks Consensus Estimate of a loss of $6.4, and an improvement from a loss of $11.2 per share a year ago, resulting in an earnings surprise of +30.31% [1] - The company generated revenues of $1.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 73.46%, compared to $1.27 million in the same quarter last year [2] - Over the last four quarters, Bolt Biotherapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2 - The stock has underperformed, losing about 47.5% since the beginning of the year, while the S&P 500 has gained 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$5.70 on revenues of $0.9 million, and for the current fiscal year, it is -$23.00 on revenues of $4.02 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for the stock's performance [8]